Abbott Laboratories (NYSE:ABT) Receives $118.30 Consensus PT from Brokerages

Abbott Laboratories (NYSE:ABT) has earned a consensus recommendation of “Moderate Buy” from the twenty-six analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $118.3043.

A number of brokerages have recently issued reports on ABT. JPMorgan Chase & Co. dropped their target price on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Royal Bank Of Canada dropped their target price on Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Leerink Partners dropped their target price on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research report on Tuesday, April 21st. Piper Sandler reissued an “overweight” rating and issued a $115.00 price objective on shares of Abbott Laboratories in a report on Monday. Finally, The Goldman Sachs Group lowered their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a report on Wednesday, May 27th.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott announced a global licensing agreement with ALZpath to develop a blood-based Alzheimer’s diagnostic test for its Alinity ci-series systems, opening a potential new growth avenue in high-demand neurology testing. Article: ALZpath signs licensing deal with Abbott to develop Alzheimer’s blood test
• Positive Sentiment: Recent commentary highlighted Abbott’s expanding diabetes franchise, especially FreeStyle Libre, and said the stock looks attractive after sector rotation pushed it lower, with one note calling it a “Buy” on growth and catalyst potential. Article: Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy
• Positive Sentiment: Multiple articles pointed to strong investor sentiment, including bullish hedge fund positioning and estimates of roughly 31% upside, suggesting Wall Street still views Abbott as a quality large-cap healthcare name. Article: How Does Wall Street View Abbott Laboratories (ABT)’s Outlook?
• Positive Sentiment: Coverage also emphasized Abbott’s dividend record, four-segment business model, and recession-resistant cash flow, which can support the stock during periods of market rotation away from defensive names. Article: 3 Dividend Aristocrat Stocks with 20%+ Upside — June 25, 2026
• Neutral Sentiment: Abbott said it will host its second-quarter earnings conference call on July 16, keeping attention on upcoming results and guidance but not changing fundamentals yet. Article: Abbott hosts conference call for second-quarter earnings
• Neutral Sentiment: Other recent pieces cited emerging-market momentum in established pharmaceuticals and new sensor distribution in Europe, adding to the bullish narrative without being major near-term stock drivers. Article: How Are Emerging Markets Supporting Abbott’s EPD Momentum?

Abbott Laboratories Stock Up 2.9%

Shares of NYSE ABT opened at $93.12 on Tuesday. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.54. The firm has a market cap of $162.19 billion, a price-to-earnings ratio of 26.08, a PEG ratio of 1.56 and a beta of 0.63. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The stock’s 50-day simple moving average is $89.23 and its 200-day simple moving average is $105.46.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. During the same period in the previous year, the company earned $1.09 earnings per share. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s payout ratio is currently 70.59%.

Insider Activity

In other news, CFO Philip P. Boudreau acquired 2,200 shares of the stock in a transaction that occurred on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the acquisition, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is owned by insiders.

Hedge Funds Weigh In On Abbott Laboratories

A number of hedge funds and other institutional investors have recently bought and sold shares of ABT. Cornerstone Financial Management LLC bought a new stake in Abbott Laboratories in the fourth quarter valued at $25,000. MidAtlantic Capital Management Inc. bought a new stake in Abbott Laboratories in the fourth quarter valued at $25,000. Purpose Unlimited Inc. bought a new stake in Abbott Laboratories in the fourth quarter valued at $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories in the fourth quarter valued at $26,000. Finally, Abound Financial LLC bought a new stake in Abbott Laboratories in the fourth quarter valued at $26,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.